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Background
Efavirenz (EFV)-containing therapies have been related to
several side-effects including hepatotoxic events and
chronic disorders in the lipid metabolism but the possible
cellular mechanisms underlying these effects have
received little study.
Methods
In this work, we evaluated the cytotoxic effects of clinical
(10–25 μM) and supraclinical (50 μM) concentrations of
EFV in various human cellular models.
Results
MTT assays upon 24 h of culture in the presence of the
drug revealed reduced viability in the human hepatoma
cell line Hep3B (significant for all three concentrations
and calculated as 84.59 ± 8.82% decrease for 50 μM EFV),
human cervix carcinoma cell line HeLa (71.92 ± 5.49%
reduction for 50 μM EFV) and primary Human Umbilical
Vein Endothelial cells (HUVEC), (96.76 ± 0.27% reduc-
tion for 50 μM EFV). This result was corroborated with 3-
day-proliferation experiments in which Hep3B were
exposed to different concentrations of EFV; a significant
reduction (60.1 ± 6.54% after 3 days) was detected with
25 μM EFV whereas cytotoxicity (97.01 ± 1.13% reduc-
tion) was observed with 50 μM, however no changes were
detected with 10 μM EFV. With the aim of analyzing the
mechanisms responsible for this diminished cellular via-
bility, we performed bivariate Annexin V/Propidium
Iodide analysis of HeLa cells using static cytometry, and
found that EFV-treated cells (4 and 8 h), presented fea-
tures of late or advanced apoptosis. We also observed a
dose-dependent translocation of two mitochondrial proa-
poptotic proteins, cytochrome c and AIF, in Hep3B cells
after EFV-treatment (4 h), which was accompanied by a
significant reduction in the mitochondrial membrane
potential (Δψm), as measured by TMRM fluorescence.
Confocal fluorescence microscopy experiments revealed a
dose-dependent activation of caspase-3 and -9 and an
absence of activation of caspase-8, pointing to EFV induc-
tion of the intrinsic (mitochondrial) apoptotic pathway.
Conclusion
In conclusion, clinical concentrations of EFV can be cyto-
toxic and lead to activation of apoptotic programmes in
common cellular models. This suggests that the therapeu-
tic range of EFV is rather narrow and also that prolonged
administration of this drug may result in HAART-related
mitochondrial dysfunction.
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